Provided by Tiger Trade Technology Pte. Ltd.

Syndax Pharmaceuticals

18.82
-1.0200-5.14%
Pre-market: 18.830.0100+0.05%08:26 EDT
Volume:1.65M
Turnover:30.97M
Market Cap:1.68B
PE:-7.50
High:19.69
Open:19.67
Low:18.40
Close:19.84
52wk High:25.59
52wk Low:12.99
Shares:89.30M
Float Shares:80.30M
Volume Ratio:1.07
T/O Rate:2.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5100
EPS(LYR):-3.2949
ROE:-255.93%
ROA:-18.67%
PB:111.30
PE(LYR):-5.71

Loading ...

US Stocks Experience Sharp Turn: Nasdaq Dives 2% in Late Trading, Micron Technology Plunges Over 4.8%

Stock News
·
Jun 09

Morgan Stanley Weighs In on NVIDIA 'Memory Halving' Rumor: A Real Shortage, Supply Constraints Emerge as AI's Biggest Hurdle

Deep News
·
Jun 08

Top 20 US Stocks by Trading Volume on June 6: Broadcom's Outlook Disappoints, Shares Extend Losses to Third Day

Deep News
·
Jun 06

Syndax grants stock options for 66,700 shares to four new employees under inducement plan

Reuters
·
Jun 05

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 05

BUZZ-U.S. STOCKS ON THE MOVE-UnitedHealth,  Pinterest, Celcuity

Reuters
·
Jun 04

BUZZ-Syndax Pharma slides after $250 mln convertible bond sale

Reuters
·
Jun 04

Syndax announces $250M convertible senior note offering due 2031

TIPRANKS
·
Jun 04

Syndax prices USD 250 million convertible senior notes due 2031

Reuters
·
Jun 04

Syndax Pharmaceuticals - to Issue $250 Mln of 2.25% Convertible Senior Notes Due 2031

THOMSON REUTERS
·
Jun 04

Press Release: Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

Dow Jones
·
Jun 04

Top 20 US Stocks by Trading Volume on June 4: Marvell Technology Extends Rally to Five Days, Hitting Another Record High

Deep News
·
Jun 04

Syndax says revumenib post-transplant maintenance study shows 90% 2-year survival in acute leukemia patients

Reuters
·
Jun 03

Syndax Pharmaceuticals to host R&D Day spotlighting revumenib, axatilimab programs

Reuters
·
Jun 01

Syndax Pharmaceuticals Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
May 22

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Syndax Pharmaceuticals (SNDX) and Olema Pharmaceuticals (OLMA)

TIPRANKS
·
May 22

Syndax revumenib post-transplant AML maintenance data wins ASCO 2026 oral slot

Reuters
·
May 22

Syndax Announces Four Revuforj® (Revumenib) Abstracts Accepted for Asco 2026, Including an Oral Presentation of Post-Transplant Data

THOMSON REUTERS
·
May 22

AI Hardware Crowded to Extreme Levels While Tech Giants Face Collective Underweighting

Deep News
·
May 20

Syndax CEO Metzger joins TD Cowen Oncology Innovation Summit fireside chat

Reuters
·
May 20